Whilst our analysis of patient samples here was limited due to small numbers, we note with interest that other investigators have indeed found that TET2 and IDH1/2 mutated bone marrow samples typically have reduced levels of 5hmC compared with nonmutated samples from patients with MDS or AML [4]. This evidence concerns the gene TET2 and myelodysplastic syndrome.